Clinical technologies utilize this signaling pathway to enhance tumor detection and management of prostate cancer through the delivery of radiopharmaceuticals into primary and metastatic prostate tumors, with PSMA-targeted PET ([68Ga] Ga-PSMA-11 (Locametz)) and ([177Lu] Lu-PSMA-617 (Pluvicto)) leading the way (35–45). Here, FOLH1 is linked to neoplasm.